Use of erythropoietin after solid organ transplantation.
Anaemia is common after solid organ transplantation. Although many impressive experimental data about the organoprotective properties of erythropoietin (EPO) have been reported, there are only scant clinical and experimental data about EPO use after solid organ transplantation. Since the treatment targets of anaemia in chronic kidney disease cannot be transferred to organ recipients for several reasons (rejection, immunosuppression, infection), the recommendations for optimal targets in the treatment of anaemia remain uncertain. Moreover, further studies will be necessary to clarify whether EPO administration might have haemoglobin-independent beneficial effects.
Schwenger
Vedat
V
Department of Nephrology, Medical University of Heidelberg, Germany, Im Neuenheimer Feld 162, 69120 Heidelberg, Germany. vedat.schwenger@med.uni-heidelberg.de
Morath
Christian
C
Zeier
Martin
M
D000740:Anemia / Q000628:therapy; D002908:Chronic Disease; D042783:Endothelial Cells / Q000166:cytology; D004921:Erythropoietin / Q000627:therapeutic use*; D016027:Heart Transplantation / Q000379:methods; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000628:therapy; D016030:Kidney Transplantation / Q000379:methods; D016031:Liver Transplantation / Q000379:methods; D016377:Organ Transplantation / Q000379:methods*; D010865:Pilot Projects; D011994:Recombinant Proteins; D012306:Risk; D013234:Stem Cells / Q000166:cytology; D016896:Treatment Outcome
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin